Drug Trial Radar · NCT06099873
Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With Influenza
Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
361
Actual
Start
Nov 30, 2023
Primary completion
Feb 13, 2025
Study completion Feb 13, 2025
Sponsor
- Lead sponsor
- Nanjing Zenshine PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary object of this study is evaluating the efficacy of ZX-7101A tablets versus placebo in the treatment of uncomplicated simple influenza in adolescents. The seongdary object is evaluating the safety of ZX-7101A tablet in the treatment of uncomplicated simple influenza in adolescents.
Conditions
- Respiratory Viral Infection
Interventions
ZX-7101ADrug
Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
PlaceboDrug
Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time to the remission of all influenza symptoms (hours)Time frame: From accepting ZX-7101A until the 15 days after the first dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University affiliated Huashan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.